CTLA4 and melanoma: Wang et al. and Naik et al. showed a significantly positive association between BMI and survival in melanoma patients treated with anti-PD1 ICI, McQuade et al. and Richtig et al. showed this positive association in patients treated with anti-CTLA4, and here we show the association in patients treated with combination anti-CTLA4 + anti-PD1 therapy [5, 6, 8, 9].